msc-2364447
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2015 (NCT02537028)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Ph1b trial planned, not yet recruiting (NCT02537028)
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545193 ↗
Also known as
- msc-2364447
- msc2364447c
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02537028 | Phase 1 | Nov 1, 2015 | Merck KGaA, Merck Serono |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 1 | 0 | 1 | 2015 |
| Merck Serono | For profit | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1